{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:32:32Z","timestamp":1792852352406,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Chemotherapy-induced nausea and vomiting (CINV) is a common adverse effect that clearly benefits from prophylactic management. Awareness of CINV and adherence to CINV management guidelines was assessed under a continuing medical education program involving a personal practice assessment (PPA)\u2014THRIVE (Training to Help Reduce CINV ratEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Forty-six medical oncologists from Canada (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921), Brazil (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), and Argentina (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095) answered an anonymous survey of their practices during patient consultations. The questionnaire was developed by a group of medical oncologist experts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The survey included data on 446 patients with multiple cancer types undergoing treatment with highly emetogenic chemotherapy (HEC; 60%) and moderately emetogenic chemotherapy (MEC; 40%). Although 65% of respondents reported using more than one guideline to establish CINV management protocols, discrepancies between respondents\u2019 classifications and major guidelines were observed, particularly for newer agents and carboplatin dosing. In addition, 11% of respondents did not discuss personal additional risk factors for CINV with patients. Regarding CINV prophylactic protocol for MEC, 39% of respondents did not include neurokinin 1 receptor antagonist (NK-1 RA) in the regimen for patients with additional risk factors on MEC. The survey also revealed significant variability in the time points adopted for assessing CINV, with 35% of physicians relying solely on spontaneous reports by patients of delayed CINV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is a pressing need to explore and support initiatives for effective implementation of guidelines and identifying the causes of nonadherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10460-0","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:16:29Z","timestamp":1773720989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Awareness of chemotherapy-induced nausea and vomiting and adherence to guidelines: results of a multinational and multicenter survey, part of the THRIVE program"],"prefix":"10.1007","volume":"34","author":[{"given":"Ricardo","family":"Caponero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Enrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lapointe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"10460_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP (2021) Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun 26:100278. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100278","journal-title":"Cancer Treat Res Commun"},{"key":"10460_CR2","unstructured":"NCCN:National Comprehensive Cancer Network; NCCN clinical practice guidelines in oncology. Antiemesis. Accessed 13 March, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"issue":"2","key":"10460_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL et al (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9(2):102195","journal-title":"ESMO Open"},{"key":"10460_CR4","unstructured":"AIOM guidelines on antiemetic therapy. Accessed 13 March, 2024. https:\/\/snlg.iss.it\/wp-content\/uploads\/2021\/07\/LG-278_terapia-antiemetica_agg2021.pdf."},{"key":"10460_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00520-004-0718-y","volume":"13","author":"SM Grunberg","year":"2005","unstructured":"Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2013an update. Support Care Cancer 13:80\u201384. https:\/\/doi.org\/10.1007\/s00520-004-0718-y","journal-title":"Support Care Cancer"},{"issue":"18 Suppl","key":"10460_CR6","first-page":"S391","volume":"24","author":"JJ Natale","year":"2018","unstructured":"Natale JJ (2018) Overview of the prevention and management of CINV. Am J Manag Care 24(18 Suppl):S391\u2013S397","journal-title":"Am J Manag Care"},{"issue":"1","key":"10460_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00520-019-04778-1","volume":"28","author":"H Woopen","year":"2020","unstructured":"Woopen H, Richter R, Chekerov R, Inci G, Alavi S, Grabowski JP et al (2020) Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. Support Care Cancer 28(1):73\u201378. https:\/\/doi.org\/10.1007\/s00520-019-04778-1","journal-title":"Support Care Cancer"},{"issue":"14","key":"10460_CR8","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"key":"10460_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08224-1","volume":"32","author":"BL Rapoport","year":"2024","unstructured":"Rapoport BL, Herrstedt J, Snow RC, Radhakrishnan V, Saito M, Navari RM et al (2024) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 32:36. https:\/\/doi.org\/10.1007\/s00520-023-08224-1","journal-title":"Support Care Cancer"},{"issue":"1","key":"10460_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08222-3","volume":"32","author":"F Scott\u00e9","year":"2023","unstructured":"Scott\u00e9 F, Schwartzberg L, Iihara H, Aapro M, Gralla R, Hesketh PJ et al (2023) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer 32(1):45. https:\/\/doi.org\/10.1007\/s00520-023-08222-3","journal-title":"Support Care Cancer"},{"issue":"8","key":"10460_CR11","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, Pel\u00e1ez I, Rodr\u00edguez-Lescure \u00c1, Pastorelli D et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the pan european emesis registry (PEER). Ann Oncol 23(8):1986\u20131992. https:\/\/doi.org\/10.1093\/annonc\/mds021","journal-title":"Ann Oncol"},{"key":"10460_CR12","doi-asserted-by":"publisher","unstructured":"Affronti ML, Schneider SM, Herndon JE 2nd, Schlundt S, Friedman HS (2014) Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Support Care Cancer 22(7):1897\u20131905. https:\/\/doi.org\/10.1007\/s00520-014-2136-0","DOI":"10.1007\/s00520-014-2136-0"},{"issue":"5","key":"10460_CR13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s13187-020-01689-2","volume":"36","author":"Z Nikbakht","year":"2021","unstructured":"Nikbakht Z, Rajabi M, Shahrasbi A, Roohi E, Hashemian F (2021) Evaluation of adherence to antiemetic treatment guidelines in patients with chemotherapy-induced nausea and vomiting in teaching hospitals in Tehran. J Cancer Educ 36(5):1022\u20131029. https:\/\/doi.org\/10.1007\/s13187-020-01689-2","journal-title":"J Cancer Educ"},{"issue":"6","key":"10460_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.6004\/jnccn.2019.7526","volume":"18","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Ruddy KJ, LeBlanc TW, Nipp RD, Binder G, Sebastiani S, Potluri R, Schmerold L, Papademetriou E, Schwartzberg L, Navari RM (2020) What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. J Natl Compr Canc Netw 18(6):676\u2013681. https:\/\/doi.org\/10.6004\/jnccn.2019.7526","journal-title":"J Natl Compr Canc Netw"},{"key":"10460_CR15","doi-asserted-by":"crossref","unstructured":"Ameno AJS, Reis AMM. Estudo da oferta de medicamentos antiem\u00e9ticos para abordagem de n\u00e1useas e v\u00f4mitos induzidos por antineopl\u00e1sicos no Brasil. Br J Health Pharm. 2020;2(2).","DOI":"10.29327\/226760.2.2-4"},{"key":"10460_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2022.01.028","volume":"166","author":"M Aapro","year":"2022","unstructured":"Aapro M, Caprariu Z, Chilingirov P, Chr\u00e1pav\u00e1 M, Curca RO, Gales L et al (2022) Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: results of the nausea\/emesis registry in oncology (NERO). Eur J Cancer 166:126\u2013133. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.028","journal-title":"Eur J Cancer"},{"issue":"1","key":"10460_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/JNSM.JNSM_10_20","volume":"4","author":"HF Al-Salloum","year":"2021","unstructured":"Al-Salloum HF, Amer YS, Alsaleh KA (2021) Monitoring the adherence to an adapted evidence-based clinical practice guideline on antiemetics in 669 patients with cancer receiving 1451 chemotherapy doses at a university oncology center in Saudi Arabia. J Nat Sci Med 4(1):33\u201339. https:\/\/doi.org\/10.4103\/JNSM.JNSM_10_20","journal-title":"J Nat Sci Med"},{"issue":"3","key":"10460_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08367-9","volume":"32","author":"R Lee","year":"2024","unstructured":"Lee R, Ku M, Je NK (2024) Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea. Support Care Cancer 32(3):190. https:\/\/doi.org\/10.1007\/s00520-024-08367-9","journal-title":"Support Care Cancer"},{"issue":"2","key":"10460_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1590\/S1679-45082015AO3097","volume":"13","author":"MS Fran\u00e7a","year":"2015","unstructured":"Fran\u00e7a MS, Us\u00f3n Junior PL, Antunes YP, Prado BL, Donnarumma CC, Mut\u00e3o TS et al (2015) Assessment of adherence to the guidelines for the management of nausea and vomiting induced by chemotherapy. Einstein (Sao Paulo) 13(2):221\u2013225. https:\/\/doi.org\/10.1590\/S1679-45082015AO3097","journal-title":"Einstein (Sao Paulo)"},{"issue":"6","key":"10460_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1517\/14656566.2013.776541","volume":"14","author":"MC Janelsins","year":"2013","unstructured":"Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR (2013) Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 14(6):757\u2013766. https:\/\/doi.org\/10.1517\/14656566.2013.776541","journal-title":"Expert Opin Pharmacother"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10460-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10460-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10460-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:41:38Z","timestamp":1776235298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10460-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10460"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10460-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This survey was conducted in accordance with the 1964 Declaration of Helsinki and its amendments. All physicians involved provided their informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"334"}}